



UNIVERSITÀ  
DEGLI STUDI  
FIRENZE

## FLORE

# Repository istituzionale dell'Università degli Studi di Firenze

### **The Simplified PADUA REal (SPARE) nephrometry system: a novel classification of parenchymal renal tumours suitable for partial**

Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione:

*Original Citation:*

The Simplified PADUA REal (SPARE) nephrometry system: a novel classification of parenchymal renal tumours suitable for partial nephrectomy / Ficarra, Vincenzo; Porpiglia, Francesco; Crestani, Alessandro; Minervini, Andrea; Antonelli, Alessandro; Longo, Nicola; Novara, Giacomo; Giannarini, Gianluca; Fiori, Cristian; Simeone, Claudio; Carini, Marco; Mirone, Vincenzo. - In: BJU INTERNATIONAL. - ISSN 1464-410X. - ELETTRONICO. - (2019), pp. 0-0. [10.1111/bju.14772]

*Availability:*

This version is available at: 2158/1157015 since: 2019-06-03T09:51:03Z

*Published version:*

DOI: 10.1111/bju.14772

*Terms of use:*

Open Access

La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (<https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf>)

*Publisher copyright claim:*

Conformità alle politiche dell'editore / Compliance to publisher's policies

Questa versione della pubblicazione è conforme a quanto richiesto dalle politiche dell'editore in materia di copyright.

This version of the publication conforms to the publisher's copyright policies.

La data sopra indicata si riferisce all'ultimo aggiornamento della scheda del Repository FloRe - The above-mentioned date refers to the last update of the record in the Institutional Repository FloRe

(Article begins on next page)

PROF. VINCENZO FICARRA (Orcid ID : 0000-0002-2447-5196)

DR. FRANCESCO PORPIGLIA (Orcid ID : 0000-0001-8567-6795)

DR. ALESSANDRO CRESTANI (Orcid ID : 0000-0001-7443-8740)

DR. ANDREA MINERVINI (Orcid ID : 0000-0001-5140-4628)

DR. GIANLUCA GIANNARINI (Orcid ID : 0000-0002-6995-246X)

Article type : Original Article

Article category: Urological Oncology

### **The Simplified PADua RENal (SPARE) nephrometry system: a novel classification of parenchymal renal tumors suitable for partial nephrectomy**

Vincenzo Ficarra<sup>1</sup>, Francesco Porpiglia<sup>2</sup>, Alessandro Crestani<sup>3</sup>, Andrea Minervini<sup>4</sup>, Alessandro Antonelli<sup>5</sup>, Nicola Longo<sup>6</sup>, Giacomo Novara<sup>7</sup>, Gianluca Giannarini<sup>3</sup>, Cristian Fiori<sup>2</sup>, Claudio Simeone<sup>5</sup>, Marco Carini<sup>4</sup>, Vincenzo Mirone<sup>6</sup>

<sup>1</sup>Department of Human and Pediatric Pathology "Gaetano Barresi", Urologic Section, University of Messina, Italy; <sup>2</sup>Division of Urology, San Luigi Gonzaga Hospital Orbassano, University of Turin, Italy; <sup>3</sup>Urology Unit, "Santa Maria Regina degli Angeli" Hospital, Adria (Ro), Italy; <sup>4</sup>Department of Urology, Careggi Hospital, University of Florence, Italy, <sup>5</sup>Urology Unit, ASST, Spedali Civili di Brescia, University of Brescia, Italy; <sup>6</sup>Department of Urology, University of Federico II of Naples, Italy; <sup>7</sup>Department of Oncologic, Surgical and Gastrointestinal Sciences, Urologic Unit, University of Padua, Italy; <sup>8</sup> Urology Unit, Academic Medical Centre Hospital "Santa Maria della Misericordia", Udine, Italy

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bju.14772

This article is protected by copyright. All rights reserved.

Corresponding author:

Prof. Vincenzo Ficarra, MD, FEBU

Department of Human and Pediatric Pathology "Gaetano Barresi",

Urologic section - University of Messina, via Consolare Valeria 1

98124 Messina, Italy

e-mail: vficarra@unime.it

twitter: @FicarraVincenzo

Keywords: renal cell carcinoma, partial nephrectomy, nephrometry scores, perioperative outcomes, pathological features

## Abstract

**Objective:** Nephrometry systems provide important information for treatment planning, patient counseling and comparison between different partial nephrectomy (PN) series. RENAL and PADUA classification are the most popular and widely used nephrometry systems.

Objective of the study are: (1) to simplify the original PADUA classification of renal tumors generating a new system able to predict equally or better the risk of overall complications in patients undergoing PN; and (2) to test if the addition of contact surface area (CSA) parameter improves the accuracy of the original and new simplified PADUA classification.

**Material and methods:** We analyzed the clinical records of 531 patients who underwent PN (open, laparoscopic and robot-assisted) for renal tumours at 5 tertiary academic referral centers from January 2014 to December 2016. The ability of each variable included in the PADUA classification to predict overall complications was tested using binary logistic regression analysis. The variables that were not statistically significant were excluded.

ed from the simplified classification. Starting from original and simplified PADUA systems, another two models were generated adding tumor CSA. ROC curve analysis was used to compare the ability of the different 4 models to predict overall complications. Binary logistic regression was used to perform both univariable and multivariable analyses looking for predictors of postoperative complications. Linear regression analysis was used to identify independent predictors of absolute change in eGFR (ACE).

**Results:** The Simplified PADUA RENal nephrometry (SPARE) score system including 1) rim location; 2) renal sinus involvement; 3) exophytic rate and 4) tumor dimension showed equal performance in comparison with the original PADUA score (AUC 0.657 Vs 0.664). Adding tumor CSA to the original (AUC 0.661) or to the simplified (AUC 0.658) PADUA scores did not increase the accuracy of both systems to predict overall complications. The SPARE system (OR 1.2 – 95%CI 1.1-1.3) was an independent predictor of postoperative overall complications. Age ( $p < 0.001$ ), BMI ( $p < 0.001$ ), Charlson index ( $p = 0.02$ ), preoperative eGFR ( $p < 0.001$ ), and tumor CSA ( $p = 0.005$ ) were independent predictors of ACE. Limitations include the retrospective design and the lack of central imaging review.

**Conclusions:** The SPARE score is composed by only 4 variables instead of the original six and its accuracy to predict overall complications is similar to that of the original PADUA score. Addition of tumor CSA was not associated with an increase in prognostic accuracy. The SPARE system could replace the original PADUA score to evaluate the complexity of tumors suitable for PN.

## Introduction

The European Association of Urology (EAU) guidelines on renal cell carcinoma (RCC) suggest the use of nephrometry systems to predict objectively the potential morbidity of nephron-sparing surgery for renal masses [1]. These tools provide important data for treatment planning, patient counseling and comparison between different partial nephrectomy (PN) series [2].

RENAL nephrometry and PADUA classification were proposed in 2009 and widely used thereafter [3,4]. Several studies externally validated both systems as predictors of overall complications, warm ischemia time (WIT), estimated blood loss (EBL) and renal function impairment [2]. Moreover, a recent comprehensive systematic review and meta-analysis evaluating the impact of host factors on robotic PN confirmed the ability of both RENAL and PADUA nephrometry systems to predict the most important intra- and post-operative outcomes [5]. Few studies compared PADUA and RENAL nephrometry scores reporting substantially overlapping ability to predict perioperative outcomes [6, 7] and renal function impairment [8]. More recently, Schiavina et al reported slightly advantages in favor of PADUA classification to predict WIT and major complications [9].

First-generation nephrometry systems are clearly imperfect and have limitations such as interobserver reproducibility, incomplete quantification of relevant anatomic features and variable correlation with perioperative outcomes. For those reasons, other investigators have proposed and evaluated second-generation nephrometry systems such as the Diameter-axial-polar (DAP) nephrometry systems [10], (the Zonal Nephro scoring system) [11] (Arterial Based Complexity (ABC) scoring system) [12]. Moreover, in 2015 Leslie et al proposed a new imaging parameter to predict the risk of complications after PN: the tumor contact surface area (CSA) [13]. Both available second-generation nephrometry systems and tumor CSA failed to be simpler, more reproducible or effective than RENAL and PADUA classifications. Therefore, it is likely that RENAL and PADUA classifications will remain the most popular in the academic community.

Similarly to TNM staging systems, we believe that the first generation of nephrometry score should be periodically updated considering the current clinical scenario and the potential role of new imaging features. Indeed, the expanding indications for nephron-sparing surgery as well as the wide diffusion of laparoscopic approaches and the significant improvement in surgical technique significantly changed the typology of the tumor treated conservatively and the morbidity of the procedures. Moreover, we need to simplify the available systems to improve their reproducibility and increase their use also in the clinical practice, beyond the clinical research setting. For such reasons, 10 years after the introduction of the PADUA score, we performed this multicenter study with the aims (1) to simplify our original classification of renal tumors generating a new

system able to predict equally or better the risk of overall complications in patients who underwent PN; and (2) to test if adding the CSA parameter improves the accuracy of the original and new simplified PADUA classification.

## Patients and methods

After local Internal Review Board (IRB) approval, we analyzed the prospectively collected clinical records of 531 consecutive patients who underwent elective PN because of a suspicion of kidney cancer at five academic, high-volume centers (Brescia, Italy; Firenze, Italy; Napoli, Italy; Torino (Orbassano), Italy; Udine, Italy;) from January 2014 to December 2016.

Patient records were extracted from each institutional database. All data were labeled with their respective institution and pooled.

All patients underwent preoperative three-dimensional abdominal CT scans or abdominal magnetic resonance imaging (MRI) to define the clinical stage and the anatomical characteristics of the tumors. All the radiologic images were prospectively evaluated by each participant center with the aim of assigning each variable (polar location; rim location; exophytic/endophytic rate, renal sinus and urinary collecting system involvement and maximal tumor size) included in the PADUA classification [4] as well as the tumor contact surface area (CSA), according to the formula described by Leslie et al [13]. The CT protocol included precontrast and postcontrast (arterial, venous, excretory phase) images. Slice thickness was 0.5 mm, and volume rendering was performed using the phase (arterial or venous) providing the clearest delineation between the tumor and the surrounding renal parenchyma. Expert and dedicated uro-radiologists calculated the tumor CSA applying 3-dimensional rendering software at the preoperative CT scan imaging. Specifically, after measurement of tumor volume and percentage of tumor located within the renal parenchyma, the total surface area (TSA) of the tumor is calculated using the formula  $4\pi r^2$  for surface area of a sphere, where  $r$  equals tumor radius. The tumor CSA is calculated by multiplying the TSA with the percentage of intraparenchymal component ( $CSA = TSA \times \text{percentage of intraparenchymal tumor}/100$ ).

Preoperative staging examination included also chest imaging (CT or x-ray), serum creatinine, serum electrolytes and liver function tests. Conversely, bone scan and brain imaging were performed when indicated by symptoms. Patients with bilateral renal tumors and/or synchronous metastases were excluded from the present analyses. Moreover, none of the patients received neoadjuvant or adjuvant treatment.

One or two experienced surgeons performed the surgical procedures in each participant center. In all cases, a traditional PN with the excision of a minimal rime of healthy parenchyma around the capsule or a simple enucleation were performed according to the surgeon preferences.

For every patient, the following demographic and preoperative variables were extracted from each institutional database: age, gender, body mass index (BMI), Charlson comorbidities index (CCI), American Society of Anesthesiologists (ASA) score, clinical tumor size, PADUA classification [4] and tumor CSA [13]. Specifically, according to the original PADUA score, tumors were stratified into low-risk (score 6–7), intermediate-risk (score 8–9), and high-risk groups (score  $\geq 10$ ) [4]. The CSA values were categorized in two groups according to the proposed cut-off value of 20 cm<sup>2</sup> [13].

Moreover, the following intraoperative variables were recorded: OR time, warm ischemia time (WIT), estimated blood loss (EBL), and transfusion rate. Three-month postoperative complications were classified according to the modified Clavien system [14]. Postoperative complications were distinguished as minor (grade 1–2) and major (grade 3–4) ones.

Pre- and post-operative eGFR were based on serum creatinine and calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula [15]. Renal function was assessed using the most recent eGFR prior to surgery and the eGFR calculated three months after the surgical procedure. Renal function dynamics were represented by the absolute eGFR change (ACE) and percentage eGFR change (PCE). ACE was calculated according the following formula:  $ACE = eGFR_{\text{postoperative}} - eGFR_{\text{preoperative}}$ . PCE was calculated by the formula,  $PCE = (eGFR_{\text{postoperative}} - eGFR_{\text{preoperative}}) / eGFR_{\text{preoperative}}$ . For each patient the 3-mo PCE greater than 20% was calculated.

Accepted Article

Excised tumors were staged according to the 2009 version of the TNM classification [16]. Moreover, the following histologic features were collected: histologic subtypes according to the World Health Organization classification [17], nuclear grade according to the Fuhrman classification [18], and surgical margin status. Positive surgical margin (PSM) was defined as cancer cells at the level of inked parenchymal excision surface.

Patients with negative surgical margins, WIT lower than 20 min and without major complications reached the Margin, Ischemia and Complications (MIC) composite outcome [19].

#### Statistical analysis

Parametric continuous variables were reported as mean  $\pm$  standard deviation (SD), whereas median and interquartile range (IQR) was used for nonparametric continuous variables. The Mann–Whitney U-test and the Kruskal-Wallis H-test were used to compare two or more nonparametric continuous variables, respectively. The Pearson chi-square test was used to compare categorical variables.

To simplify the original PADUA classification, the ability of each variable to predict overall complications was tested using the binary logistic regression analysis. The variables which were not statistically significant were excluded from the simplified classification. The Odds Ratio (OR) values recorded for the variables predicting the overall complications were used to assign the new score for each tested category.

Starting from original and simplified PADUA systems, two other models were generated adding the score assigned to the CSA categories [13]. ROC curve analysis was used to compare the ability of the different 4 models to predict overall complications.

Binary logistic regression was used to perform both univariable and multivariable analyses looking for predictors of overall postoperative complications. Linear regression analysis was used to identify independent predictors of ACE. Beyond the new simplified nephrometry system, the following preoperative covariates were included in multivariate models: age, BMI, comorbidities index, and preoperative eGFR and tumor CSA.



For all statistical analyses, a two-sided  $p < 0.05$  was considered statistically significant. All data were analyzed with SPSS v. 23 statistical software (IBM Corp., Armonk, NY, USA).

## Results

Table 1 summarizes the preoperative characteristics of 531 patients included in the present study (Table 1). PNs were performed using an open approach in 237 (44.6%) cases, a pure laparoscopic approach in 152 (28.6%) cases, and a robot-assisted approach in the remaining 142 (26.7%) cases. Perioperative and pathologic outcomes were reported in Table 2 (Table 2).

Three-month postoperative complications were recorded in 140 (26.4%) patients, including 110 (20.7%) patients with minor and 30 (5.7%) with major complications. Specifically, minor complications were represented by prolonged fever/infection requiring intravenous therapy (IV) in 45 (8.4%) patients; hematoma/hematuria requiring blood transfusion in 42 (7.9%) cases; cardiovascular diseases requiring medical therapies in 15 (2.8%) cases and deep venous thrombosis in 8 (1.5%) cases. Major complications included arterio-venous fistula requiring percutaneous embolization in 18 (3.3%) cases; urinary leakage requiring ureteral JJ placement in 8 (1.5%) cases; acute renal insufficiency requiring temporary dialysis in 4 (0.7%) cases.

Table 3 shows the ability of each anatomical and topographic variable to predict the risk of overall complications in univariable analysis. A new score for each category was assigned according to the odds ratio value observed (Table 3).

Figure 1 shows the accuracy of different nephrometry systems generated from the original PADUA classification to predict overall complications (Fig. 1). Specifically, the Simplified PADUA RENal nephrometry (SPARE) score including 1) rim location; 2) renal sinus involvement; 3) exophytic rate and 4) tumor dimension was considered as the simplest with AUC value similar to the others ( $p=0.9$ ). Moreover, adding the tumor CSA to the original or simplified PADUA score did not increase the performance of either

models ( $p=0.8$ ). Notably, the accuracy of tumor size alone was significantly lower than both PADUA classification ( $p=0.02$ ) and SPARE system ( $p=0.03$ ) (Fig. 1).

Table 4 reports the most important perioperative outcomes stratified according to the SPARE nephrometry score (Table 4). In details, overall complications were detected in 63/342 (18.4%) patients in the low risk group (score 0-3); in 59/152 (38.8%) patients included in the intermediate risk group (score 4-7) and in 18/37 (48.6%) patients classified as high risk category (score 8-10) ( $p<0.001$ ), respectively. Moreover, the new risk stratification was able to differentiate operative time ( $p<0.001$ ), cases not requiring ischemia ( $p<0.001$ ), WIT ( $p=0.006$ ), EBL ( $p<0.001$ ), and percentage of patients reaching the MIC composite outcome ( $p<0.001$ ) (Table 4).

Interestingly, the SPARE system was able to predict the risk of overall complications also in the subgroups of patients treated either by open ( $p=0.004$ ), laparoscopic ( $p<0.001$ ) or robot-assisted PN ( $p=0.009$ ). Similarly the SPARE system predicted overall complications in the subgroups of patients who received a simple enucleation ( $p=0.002$ ) or a minimal partial nephrectomy ( $p<0.001$ ) (Table 5).

Multivariable analysis showed that only age (OR 1.0 – 95%CI 1.0-1.1) and SPARE nephrometry score (OR 1.2 – 95%CI 1.1-1.3) were independent predictors of postoperative complications. Table 5 reports the univariable and multivariable analyses identifying the preoperative independent predictors of overall complications (Table 6).

The median value of ACE was -6.5 (IQR -18 to +1.5). Three months after surgery 136 (25.6%) patients showed a PCE greater than 20%. Linear logistic regression analysis showed that age ( $p<0.001$ ); BMI ( $p<0.001$ ); Charlson index ( $p=0.02$ ); preoperative eGFR ( $p<0.001$ ) and tumor CSA ( $p=0.005$ ) were independent predictors of ACE (Table 7).

## Discussion

Rim location, renal sinus involvement, exophytic rate and tumor size can be combined in a new Simplified PADUA Renal (SPARE) nephrometry score able to predict overall complications in patients who underwent PN for renal tumors. Specifically, the SPARE

Accepted Article

system eases the nephrometry score assignment in the clinical practice maintaining the same accuracy of the original PADUA score. Table 8 summarizes the variables and scores included in original PADUA classification compared to those included in the SPARE system (Table 8). Moreover, tumor CSA does not increase the accuracy of both original and simplified PADUA score to estimate the risk of complications. Conversely, tumor CSA seems to be more appropriate to predict the absolute 3-mo change of eGFR in comparison with the SPARE system.

In the last decade, nephrometry systems were widely used in the clinical practice to estimate the complexity of tumors suitable for PN and consequently improve the decision-making and patient's counseling processes. Moreover, the introduction of nephrometry systems increased the quality of clinical researches improving data interpretation and comparison between different series. RENAL nephrometry and PADUA classification were proposed in 2009 and represented together with the Centrality Index the first-generation of nephrometry score [3, 4, 20].

Both PADUA and RENAL nephrometry systems communicate geographic location data of the tumor. Conversely the Centrality Index provides a continuous index based on tumor size and distance from the periphery of the tumor to the center of the kidney. Available studies included in a review published in 2015, showed that RENAL nephrometry score and PADUA classification were the most popular and used in comparison to Centrality index. Interestingly, validation studies of these first-generation nephrometry systems showed conflicting results, probably as consequence of the heterogeneity of the evaluated series [2]. More recently, Cacciamani et al performed a systematic review and meta-analysis of the literature including all surgical series and comparative studies involving patients treated by robot-assisted PN (RAPN). When the reviewed series were stratified according to the RENAL nephrometry score, complex cases showed longer operative time and WIT; higher EBL and overall complications in comparison with less complex cases. Conversely, the RENAL nephrometry score failed to identify any difference between low and high complex tumors in terms of transfusion rate, major complications, length of hospital stay, renal function, and PSM rates. Similarly, PADUA score stratified appropriately low and high complex cases in terms of all previous perioperative outcomes with the exception of renal function and PSM rate [5].

Accepted Article

Interestingly, for the first time, our study showed that the accuracy of original PADUA classification was not diminished removing some features such as polar location and upper collecting system involvement. The polar location was removed because it was not predictive of overall complications in univariable analysis. Similarly, clustering together in a single variable the renal sinus and UCS involvement, we observed that cases with only UCS involvement were similar to those cases with any involvement. Therefore, UCS involvement was removed from the system. Consequently, the new simplified SPARE system should be easier to calculate considering that the polar location and the UCS involvement are two time-consuming steps of the original PADUA score. Dedicated studies analyzing the inter- and intra-observer concordance of original and simplified PADUA score will be needed to confirm such hypothesis.

All the variables included in the new SPARE system were already present in the RENAL nephrometry system with the exception of the tumor location at level of medial or lateral rim of the kidney [3]. Indeed, the exophytic rate and the tumor size are stratified using the same cut-off values and the categories identified by the variable “(N)earness to the collecting system or sinus” can be easily mutated in absence ( $\geq 4$  mm) or presence ( $< 4$  mm) of renal sinus involvement according to SPARE system.

Other preoperative imaging features have been recently proposed in the Literature beyond the parameters included in the RENAL and PADUA systems. In this context, the tumor CSA is the most extensively investigated and has been externally validated [13; 21-23]. For the first time, our study showed that the addition of tumor CSA to the original PADUA score or to the SPARE system did not increase their accuracy in predicting overall complications. However, our study confirmed the role of tumor CSA as independent predictors of renal function impairment in a model adjusted for all the most important patient-related factors such as age, BMI, comorbidity index and preoperative eGFR. Conversely, the SPARE system was not an independent predictor of renal function impairment. These data confirmed other studies showing that original PADUA score was not a predictor of 3-mo renal function impairment [5, 23]. Therefore, tumor CSA could help surgeons to tailor the most appropriate dissection strategy, e.g., preferring simple enucleation instead of a wider resection of healthy parenchyma in patients with values higher than  $20 \text{ cm}^2$ .

Accepted Article

Limitations of the present study include the retrospective design and the lack of central imaging review to assign the variables included in the PADUA score and calculate the tumor CSA area. Moreover, we did not calculate the amount of sacrificed healthy parenchyma during the extirpative phase of the procedure applying specific formulas based on the pre- and postoperative imaging or measuring the rime of healthy parenchyma around the tumor on the surgical specimens. However, in all cases the Authors minimized the excisional volume loss performing a simple enucleation or a minimal PN. Last, similarly to the imaging features, the pathology slides review was not centralized. The lack of a validation is a further limitation of the study. Obviously, the SPARE system need to be externally validated in the context of further single and multicenter studies.

## Conclusions

Ten years after the proposal of original PADUA score based on six anatomical and topographic tumor-related features, we proposed a new simplified version of this nephrometry system to predict the risk of postoperative complications. Only four features (rim location, renal sinus involvement, exophytic rate and maximum tumor size) composedt the new Simplified PADUA Renal (SPARE) nephrometry score.

The accuracy of the new simplified system was similar to that recorded for original PADUA score and it is not increased by the addition of the tumor CSA parameter. The SPARE nephrometry score correlated with all the most important perioperative outcomes and was an independent predictor of overall complications. Interestingly, the new simplified system was generated from a multisurgeon, multicenter series including more than 50% of cases performed via a minimally invasive approach. Moreover, about 30% of patients had PN for tumors >4 cm. For those reasons, the SPARE system could replace the original PADUA score to evaluate the complexity of tumors suitable for nephron-sparing surgery. Obviously, large, multicenter studies are needed to obtain an external validation of this simplified nephrometry system. Interestingly, the tumor CSA confirmed to be an important predictors of renal function impairment together with the most relevant patient-related factors.

## References

1. Ljungberg B, Bensalah K, Canfield S et al. EAU guidelines on renal cell carcinoma: 2014 update. *Eur Urol*. 2015; 67:913-24.
2. Klatte T, Ficarra V, Gratzke C et al. A literature review of renal surgical anatomy and surgical strategies for partial nephrectomy. *Eur Urol* 2015; 68: 980-992.
3. Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. *J Urol* 2009; 182: 844–53.
4. Ficarra V, Novara G, Secco S et al. Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. *Eur Urol*. 2009; 56: 786-93.
5. Cacciamani GE, Gill T, Medina L et al. Impact of host factors on robotic partial nephrectomy outcomes: comprehensive systematic review and meta-analysis. *J Urol*. 2018; 200: 716-30
6. Hew MN, Baseskioglu B, Barwari K et al. Critical appraisal of the PADUA classification and assessment of the R.E.N.A.L. nephrometry score in patients undergoing partial nephrectomy. *J Urol* 2011; 186: 42–6.
7. Bylund JR, Gayheart D, Fleming T et al. Association of Tumor Size, Location, R.E.N.A.L., PADUA and Centrality Index Score with Perioperative Outcomes and Postoperative Renal Function. *J Urol* 2012; 188: 1684-89.
8. Zhang ZY, Tang Q, Li XS et al. Clinical analysis of the PADUA and the RENAL scoring systems for renal neoplasms: a retrospective study of 245 patients undergoing laparoscopic partial nephrectomy. *Int J Urol* 2014; 21: 40–44.
9. Schiavina R, Novara G, Borghesi M et al. PADUA and R.E.N.A.L. nephrometry scores correlate with perioperative outcomes of robot-assisted partial nephrectomy: analysis of the Vattikuti Global Quality Initiative in Robotic Urologic Surgery (GQI-RUS) database. *BJU Int* 2017; 119: 456-63.
10. Simmons MN, Hillyer SP, Lee BH et al. Diameter-axial polar nephrometry: integration and optimization of R.E.N.A.L. and centrality index scoring systems. *J Urol* 2012; 188: 384–90.
11. Hakky TS, Baumarten AS, Allen B et al. Zonal NePhRO Scoring System: a superior renal tumor complexity classification model. *Clinical Genitourinary Cancer* 2014; 12: 13-8.
12. Spaliviero M, Poon BY, Karlo CA et al. An arterial based complexity (ABC) scoring system to assess the morbidity profile of partial nephrectomy. *Eur Urol* 2016; 69: 72–9.
13. Leslie S, Gill IS, de Castro A et al. Renal tumor contact surface area: a novel parameter for predicting complexity and outcomes of partial nephrectomy. *Eur Urol* 2014; 66: 884-93.
14. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation on a cohort of 6,336 patients and results of a survey. *Ann Surg* 2002; 240: 205-13.
15. Levey AS, Inker LA. Assessment of Glomerular Filtration Rate in Health and Disease: A State of the Art Review. *Clin Pharmacol Ther*. 2017; 102: 405-19.
16. Greene FL, Gospodarowicz M, Wittekend C et al. American Joint Committee on Cancer (AJCC) staging manual. ed. 7. Philadelphia,PA: Springer; 2009.

- Accepted Article
17. Eble JN, Sauter G, Epstein JI et al. Pathology and genetics of tumors of the urinary system and male genital organs. World Health Organization classification of tumors. Lyon, France: IARC Press; 2004.
  18. Fuhrman S, Lasky LC, Limas L. Prognostic significance of morphologic parameters in renal cell carcinoma. *Am J Surg Pathol* 1982;6: 655-63.
  19. Lista G, Buffi N, Lughezzani G et al. Margin, Ischemia, and Complications system to report perioperative outcomes of robotic partial nephrectomy: A European multicenter observational study (EMOS Project). *Urology* 2015; 85: 589-95
  20. Simmons MN, Ching CB, Samplaski MK et al. Kidney tumor location measurement using the C index method. *J Urol* 2010; 183: 1708-13.
  21. Haifler M, Ristau BT, Higgins AM et al. External Validation of Contact Surface Area as a Predictor of Postoperative Renal Function in Patients Undergoing Partial Nephrectomy. *J Urol*. 2018; 199: 649-54.
  22. Ficarra V, Crestani A, Bertolo R et al. Tumor Contact Surface Area as predictor of postoperative complications and renal function in patients undergoing partial nephrectomy for renal tumors. *BJU Int* 2019; 123: 639-45.

**Table 1: Demographic, preoperative and imaging characteristics of 531****Patients included in the analysis**

<b>Variables</b>	<b>Total cases (n=531)</b>
Median (IQR) Age, years	64 (55 – 72)
Male gender (%)	353 (66.5%)
Median (IQR) BMI, kg/m <sup>2</sup>	25.7 (23.6-28)
Charlson comorbidity index, n (%)	
- 0	416 (78.3%)
- >0	115 (21.7%)
Symptoms at diagnosis, n (%)	
- absent	461 (86.8%)
- present	70 (13.2%)
Median (IQR) clinical size, cm	3.2 (2.3-4.4)
Polar location, n (%)	
- Upper	175 (33%)
- Middle	223 (42%)
- Lower	133 (25%)
Rime location, n (%)	
- Lateral	315 (59.3%)
- Medial	216 (40.7%)
Renal sinus involvement, n (%)	
- Absent	393 (74%)
- Present	138 (26%)
Upper collecting system involvement, n (%)	
- Absent	380 (71.6%)
- Present	151 (28.4%)
Exophytic Rate, n (%)	
- ≥ 50%	251 (47.3%)
- < 50%	234 (44.1%)
- endophytic	



	46 (8.7%)
Tumor size categories (cm), n (%)	
- ≤ 4	364 (68.5%)
- 4.1 - 7	142 (26.7%)
- > 7	25 (4.7%)
Median (IQR) PADUA score	8 (7-10)
PADUA risk stratification	
- low	198 (37.3%)
- intermediate	197 (37.9%)
- high	136 (25.6%)
Median (IQR) Contact Surface Area (cm <sup>2</sup> )	14.2 (7.4-25.1)
Contact Surface Area (cm <sup>2</sup> ), n (%)	
- ≤ 20	349 (65.7%)
- >20	182 (34.3%)
Median (IQR) preoperative eGFR , ml/min	82.2 (66.8-100.4)

**Table 2: Intraoperative and pathologic features of 531 patients included in the analysis**

<b>Variables</b>	<b>Total cases (n=531)</b>
Approach, n (%)	
- open	237 (44.6%)
- laparoscopic	152 (28.6%)
- robot-assisted	142 (26.7%)
Median (IQR) OR, min	119 (90-150)
Ischemia, n (%)	
- zero	188 (35.4%)
- warm	343 (64.6%)
Median (IQR) WIT, min (n=343)	16 (12-20)
Median (IQR) EBL, ml	100 (50-200)
Median (IQR) LOS, days	6 (5-7)
Histologic subtype, n (%)	
- benign	109 (20.5%)
- clear cell	293 (55.2%)
- non clear cell	129 (24.3%)
pT, stage, n (%)	
- pT1a	274 (64.9%)
- pT1b	101 (23.9%)
- pT2	33 (7.8%)
pT3a	14 (3.3%)
Nuclear Grade, n (%)	
- grade 1	56 (13.3%)
- grade 2	248 (58.8%)
- grade 3	99 (23.5%)
grade 4	19 (4.5%)
Surgical margins, n (%)	
- negative	412 (97.6%)
- positive	10 (2.4%)

Median (IQR) postoperative eGFR, ml/min	81 (64-100)
PCE greater than 20%, n (%)	136 (25.6%)

**Table 3: Binary logistic regression analysis shows the accuracy of each anatomical and topographic parameter to predict the risk overall complications. A new score for each category was assigned according to the reported odds ratio**

Variables	OR (95% Confidence Interval)	p Value	Score
Polar location - Upper/Lower - Medium	Referent 1.3 (0.9-1.9)	0.2	0 1
Rim location - Lateral - Medial	Referent 1.8 (1.2-2.6)	0.003	0 2
Renal sinus involvement - Absent - Present	Referent 2.5 (1.6-3.8)	<0.001	0 3
UCS involvement - Absent - Present	Referent 2.0 (1.3-3.0)	0.001	0 2
Sinus/UCS involvement - Absent - Only UCS - Only renal sinus - Both	Referent 1.6 (0.7-3.3) 3.6 (1.6-8.1) 2.5 (1.6-3.9)	0.23 0.003 <0.001	Not applica- ble
Exophytic rate - ≥ 50% - < 50% - endophytic	Referent 1.3 (0.9-2.0)	0.16	0 1

	2.0 (1.0-3.9)	0.04	2
Maximum Tumor size			
- ≤ 4 cm	Referent		0
- 4.1-7 cm	1.8 (1.1-2.7)	0.01	2
- > 7 cm	3.8 (1.7-8.8)	0.001	4
Tumor CSA			
- ≤ 20 cm <sup>2</sup>	Referent		0
- > 20 cm <sup>2</sup>	2.0 (1.3-3.0)	<0.001	2

**Table 4: The most important perioperative outcomes are stratified according to the different risk categories identified according to the Simplified PAdua REal (SPARE) nephrometry score.**

Variables	Low risk (score 0-3) (n= 342)	Intermediate risk (score 4- 7) (n= 152)	High risk (score 8- 10) (n=37)	P Value
Median (IQR) OR, min	110 (80-140)	130 (100-168)	150 (115-205)	<0.001
No ischemia, n (%)	148 (43.3%)	37 (24.3%)	3 (8.1%)	<0.001
Median (IQR) WIT, min	15 (12-20)	16 (12-21)	19 (15-27)	0.006
Median (IQR) EBL, ml	100 (50-200)	145 (55-300)	200 (100-425)	<0.001
Intraoperative transfusion, n (%)	10 (2.9%)	3 (2%)	0 (0%)	0.5
Overall postoperative complications, n (%)	63 (18.4%)	59 (38.8%)	18 (48.6%)	<0.001
Major (Grade 3-4) postoperative complications	12 (3.5%)	15 (9.9%)	3 (8.1%)	0.01
Margin, Ischemia, Complications (MIC) reached, n (%)	258 (75.4%)	87 (57.2%)	15 (40.5%)	<0.001
Absolute change in eGFR (ACE)	-6 (-15 – 0.02)	-7.3 (-21.7 – 5.6)	-10 (-26 – 2.3)	0.6

Table 5: Correlation between Simplified PAdua REnal (SPARE) nephrometry score and presence of overall complications stratified according to surgical approach and technique.

<b>Variables</b>	<b>Cases (%)</b>	<b>Median SPARE value (IQR)</b>	<b>P Value</b>
Open Partial Nephrectomy (n= 237)			0.004
- no complication	162	2 (1-5)	
- complications	75	4 (2-5)	
Laparoscopic Partial Nephrectomy (n= 152)			<0.001
- no complication	109	2 (1-3)	
- complications	43	3 (2-6)	
Robot-assisted Partial Nephrectomy (n= 142)			0.009
- no complication	120	1 (0-4)	
- complications	22	4 (1-7)	
Simple Enucleation (n= 136)			0.002
- no complication	109	1 (0-2)	
- complications	27	3 (0-5)	
Minimal Partial Nephrectomy (n= 395)			<0.001
- no complication	282	2 (1-5)	
- complications	113	4 (2-6)	

**Table 6: Univariable and multivariable analyses to predict overall postoperative complications**

Variables	Univariable analyses		Multivariable analysis	
	OR (95% CI)	P Value	OR (95% CI)	P Value
Gender				
- male	Referent	0.7		
- female	0.9 (0.6-1.4)			
Age				
(continuous)	1.0 (1.0-1.1)	0.001	1.0 (1.0-1.1)	<0.001
BMI				
(continuous)	1.0 (0.9-1.1)	0.2	1.0 (0.9-1.1)	0.3
Charlson score				
- 0-1	Referent	0.8	Referent	
- > 1	1.1 (0.7-1.6)		1.0 (0.6-1.6)	0.9
Symptoms				
- absent	Referent	0.30		
- present	1.3 (0.8-2.3)			
Clinical tumor size				
(continuous)	1.0 (1.0-1.1)	<0.001		
Preoperative eGRF				
(continuous)	1.0 (0.9-1.1)	0.1	1.0 (0.9-1.0)	0.8
SPARE <sup>o</sup> score				
	1.2 (1.1-1.3)	<0.001	1.2 (1.1-1.3)	<0.001
SPARE <sup>o</sup> risk				



- low (score 0-3)	Referent			
- interm.(score 4-7)	2.8 (1.8-4.3)	<0.001		
- high (score 8-10)	4.2 (2.1-8.4)	<0.001		
Tumor CSA (continuous)	1.1 (1.0-1.1)	<0.001	1.1 (1.0-1.1)	0.2
Tumor CSA	Referent			
- $\leq 20 \text{ cm}^2$				
- $> 20 \text{ cm}^2$	2.0 (1.4-3.0)	<0.001		

\*Simplified PAdua REnal nephrometry system including rime location, exophytic rate, renal sinus involvement and tumor size.

**Table 7: Multivariable (linear regression analysis) analysis to identify independent predictors of absolute change in eGFR (ACE)**

<b>Variables</b>	<b>B (95% CI)</b>	<b>P Value</b>
Age (continuous)	-0.114 (-0.6 / -0.3)	<0.001
BMI (continuous)	0.06 (0.3 / 1.1)	0.001
Charlson score (continuous)	-0.046 (-3.1 / -0.2)	0.02
Preop eGFR (continuous)	-0.924 (-0.9 / - 0.8)	<0.001
SPARE <sup>o</sup> score (continuous)	0.02 (-0.4/ 1.2)	0.4
Tumor CSA (continuous)	-0.06 (-0.3 / -0.05)	0.005

<sup>o</sup>Simplified PAdua REnal nephrometry system including rime location, exophytic rate, renal sinus involvement and tumor size.

Table 8: Comparison between original PADUA classification and new simplified SPARE nephrometry system.

<b>Variables</b>	<b>Original PADUA score</b>	<b>SPARE score</b>
Polar location - Upper/Lower - Medium	1 2	Not included
Rim location - Lateral - Medial	1 2	0 2
Renal sinus involvement - Absent - Present	1 2	0 3
UCS involvement - Absent - Present	1 2	Not included
Exophytic rate - $\geq 50\%$ - $< 50\%$ - endophytic	1 2 3	0 1 2
Maximum Tumor size - $\leq 4$ cm - 4.1-7 cm - $> 7$ cm	1 2 3	0 2 4




Figure 1: ROC Curve analysis shows the accuracy (AUC – 95% CI) of different nephrometry systems generated from the original PADUA classification to predict overall complications. The differences between the AUCs were not statistically significant ( $p=0.9$ ). The accuracy of tumor size resulted significantly worse in comparison with nephrometry system models ( $p=0.02$ ).

Model 1 (blue) (original PADUA score): AUC 0.664 (0.612-0.715)

Model 2 (green) (original PADUA score + tumor CSA): AUC 0.661 (0.609-0.713)

Model 3 (grey) (Simplified PADUA Renal nephrometry score including rime location, exophytic rate, renal sinus involvement and tumor size): AUC 0.657 (0.604-0.710)

Model 4 (violet) (Simplified PADUA renal nephrometry score + tumor CSA): AUC 0.658 (0.606-0.711)

Model 5 (orange) (tumor size): AUC 0.57 (0.52-0.63)